Exploring the Safety & Efficacy Profile of ABBV-400 Across Solid Tumours & Laying the Path Forward for c-MET-Targeted ADCs
- Laying out the history and progress made developing ADCs and other therapeutics against c-Met
- Detailing the safety and efficacy profile of ABBV-400 across lung, CRC and solid tumour indications
- Exploring lessons learned to optimise ABBV-400 clinical profile and evaluating the concept of ADCs as targeted therapies